ReviewSeminars in radiation oncology2011
Hepatic radiation toxicity: avoidance and amelioration.
Review in Seminars in radiation oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 237 citations in OpenAlex.
- Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.JAMA oncology · 2018Trial
- Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions.Journal of Korean medical science · 2015Trial
- Radiotherapy and cytokines: A systems view of immunotherapy and toxicity (Review).International journal of molecular medicine · 2026Review
- A pig model of human radiation-induced veno-occlusive liver disease reveals ferroptosis as a therapeutic target.Cell reports. Medicine · 2026Article
- Kupffer Cell-Derived Interleukin-6 Aggravates Radiation-Induced Liver Disease by Activating Hepatocyte STAT3 to PromoteAdvances in radiation oncology · 2026Article
- Establishment and comparative analysis of radiation-induced liver disease in normal and fibrotic rat models.Precision radiation oncology · 2026Article
- SFRT combined with immunotherapy for bulky hepatic metastasis from pancreatic acinar cell carcinoma: a case report.Frontiers in oncology · 2026Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
- Analysis of metabolic liver function and MR-morphological cholestatic parameters after SBRT of liver metastases.Radiation oncology (London, England) · 2025Article
- Chronic liver disease and radiation-induced second primary liver malignancy: a retrospective cohort based on SEER database 2010-2021.Annals of medicine and surgery (2012) · 2025Article
- Gasdermin D aggravates a mouse model of radiation-induced liver disease by promoting chemokine secretion and neutrophil recruitment.Nature communications · 2025Article
- Liver quad culture chip as a model for radiation injury research.Scientific reports · 2025Article
- Radiotherapy toxicities: mechanisms, management, and future directions.Lancet (London, England) · 2025Review
- Clinical Outcomes and Hepatic Toxicity of Combined Intensity Modulated Radiotherapy and PD-1 Inhibitors in Child-Pugh Class B Advanced Hepatocellular Carcinoma.ImmunoTargets and therapy · 2025Article
- Radiation induced liver injury (RILI) evaluation using longitudinal computed tomography (CT) in image-guided precision murine radiotherapy.Precision radiation oncology · 2024Article
- Review
- Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study.Japanese journal of clinical oncology · 2024Article
- High dose proton and photon-based radiation therapy for 213 liver lesions: a multi-institutional dosimetric comparison with a clinical perspective.La Radiologia medica · 2024Article
- Review
- Biochemical Safety of SBRT to Multiple Intrahepatic Lesions for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The refinement of radiation therapy and radioembolization techniques has led to a resurgent interest in radiation-induced liver disease (RILD). The awareness of technical and clinical parameters that influence the chance of RILD is important to guide patient selection and toxicity minimization strategies. "Classic" RILD is characterized by anicteric ascites and hepatomegaly and is unlikely to occur after a mean liver dose of approximately 30 Gy in conventional fractionation. By maintaining a low mean liver dose and sparing a "critical volume" of liver from radiation, stereotactic delivery techniques allow for the safe administration of higher tumor doses. Caution must be exercised for patients with hepatocellular carcinoma or pre-existing liver disease (eg, Child-Pugh score of B or C) because they are more susceptible to RILD that can manifest in a nonclassic pattern. Although no pharmacologic interventions have yet been proven to mitigate RILD, preclinical research shows the potential for therapies targeting transforming growth factor-β and for the transplantation of stem cells, hepatocytes, and liver progenitor cells as strategies that may restore liver function. Also, in the clinical setting of veno-occlusive liver disease after high-dose chemotherapy, agents with fibrinolytic and antithrombotic properties can reverse liver failure, suggesting a possible role in the setting of RILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.